An integrated in vitro model of perfused tumor and cardiac tissue

灌注肿瘤和心脏组织的集成体外模型

基本信息

  • 批准号:
    9095929
  • 负责人:
  • 金额:
    $ 73.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-24 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cancer and cardiovascular disease remain the two leading causes of death in the United States. Progress in treatment to reduce morbidity and mortality will include the development of new drugs. Recent advances in induced pluripotent stem (iPS) cell technology, tissue engineering, and microfabrication techniques have created a unique opportunity to develop 3-D microphysiological systems that more accurately reflect in vivo human biology when compared to 2-D "flat" systems or animal models. The primary goal of this project is to create 3-D micro-organ systems using iPS technology that simulate 1) the microcirculation, 2) cardiac muscle, and 3) solid tumor during the UH2 phase, and then combine these micro-organs into three integrated micro- organ systems that simulate 1) perfused cardiac muscle, 2) perfused solid tumor, and 3) perfused cardiac muscle and solid tumor during the UH3 phase. The platform will be initially validated to predict anti-cancer efficacy while minimizing cardiac muscle toxicity. The broader implication of this project is the creation of a platform technology that can accurately and affordably simulate the complex interplay between the major human organ systems, including the response to new and existing drugs. A critical feature will be blood flow through a human microcirculation (capillaries and larger microvessels), which is necessary to overcome diffusion limitations of nutrients and waste products in realistic 3-D cultures, and serves to integrate multiple organ systems. This is a necessary and critical feature of any platform that seeks to simulate integrated human organ systems, and our preliminary studies demonstrate this capability. Secondary goals of the project include achieving: 1) flexibility in the design such that alternate organ functions (e.g., liver) can be eaily inserted, removed, or rearranged (i.e., "plug-n-play"); 2) reproducibility in the manufacturing process and the biological response; 3) portable design that is palm-sized; 4) the use of iPS cell technology to create patient-specific (or "personalized") drug screening, and 5) non-invasive and non-destructive optical imaging methods to rapidly assess the metabolic state of a cell. The results should produce a new paradigm for efficient and accurate drug and toxicity screening, initially for anti-cancer drugs with minimal cardiac side effects, and a platform technology that can be eventually used to integrate all of the major organs of the human body.
描述(申请人提供):癌症和心血管疾病仍然是美国的两大主要死亡原因。减少发病率和死亡率的治疗进展将包括新药的开发。诱导多能干细胞(IPS)技术、组织工程学和微制造技术的最新进展为开发三维微生理系统创造了独特的机会,与二维平面系统或动物模型相比,三维微生理系统可以更准确地反映体内的人类生物学。该项目的主要目标是利用iPS技术创建三维微器官系统,模拟UH2阶段的微循环、2)心肌和3)实体肿瘤,然后将这些微器官组合成三个集成的微器官系统,模拟1)灌流的心肌、2)灌流的实体肿瘤和3)UH3阶段的灌流心肌和实体肿瘤。该平台将进行初步验证,以预测抗癌效果,同时将心肌毒性降至最低。该项目的更广泛影响是创造了一种平台技术,可以准确和负担得起地模拟主要人体器官系统之间的复杂相互作用,包括对新药物和现有药物的反应。一个关键特征将是通过人体微循环(毛细血管和较大的微血管)的血液流动,这是克服现实3-D培养中营养物质和废物的扩散限制所必需的,并用于整合多个器官系统。这是任何试图模拟集成人体器官系统的平台的必要和关键功能,我们的初步研究证明了这一能力。该项目的次要目标包括:1)设计的灵活性,以便可以轻松地插入、移除或重新排列替代器官功能(如肝脏)(即,“即插即用”);2)制造过程和生物响应的重复性;3)手掌大小的便携式设计;4)使用iPS细胞技术创建针对患者的(或“个性化”)药物筛选;5)非侵入性和无损的光学成像方法,快速评估细胞的代谢状态。这些结果应该会产生一种有效和准确的药物和毒性筛选的新范式,最初是对心脏副作用最小的抗癌药物的筛选,以及一种最终可用于整合人体所有主要器官的平台技术。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven CARL George其他文献

Steven CARL George的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven CARL George', 18)}}的其他基金

An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10609156
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10550076
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10488180
  • 财政年份:
    2021
  • 资助金额:
    $ 73.16万
  • 项目类别:
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10705910
  • 财政年份:
    2021
  • 资助金额:
    $ 73.16万
  • 项目类别:
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10223815
  • 财政年份:
    2021
  • 资助金额:
    $ 73.16万
  • 项目类别:
An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection
人体骨髓和外周感染的集成体外 3D 模型
  • 批准号:
    10649625
  • 财政年份:
    2021
  • 资助金额:
    $ 73.16万
  • 项目类别:
Training Program in Cardiovascular Applied Research and Entrepreneurship
心血管应用研究与创业培训项目
  • 批准号:
    8551458
  • 财政年份:
    2013
  • 资助金额:
    $ 73.16万
  • 项目类别:
An integrated in vitro model of perfused tumor and cardiac tissue
灌注肿瘤和心脏组织的集成体外模型
  • 批准号:
    9264734
  • 财政年份:
    2012
  • 资助金额:
    $ 73.16万
  • 项目类别:
An integrated in vitro model of perfused tumor and cardiac tissue
灌注肿瘤和心脏组织的集成体外模型
  • 批准号:
    8516127
  • 财政年份:
    2012
  • 资助金额:
    $ 73.16万
  • 项目类别:
A 3-D In Vitro Platform of Tumor Metastasis (PQ24)
肿瘤转移的 3D 体外平台 (PQ24)
  • 批准号:
    8871694
  • 财政年份:
    2012
  • 资助金额:
    $ 73.16万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 73.16万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 73.16万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 73.16万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 73.16万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 73.16万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 73.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了